drugset / Trial / NCT06027567
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
Phase 4
Completed
38 enrolled
Rigmor Højland Jensen
Odense University Hospital · collabRigshospitalet, Denmark · collabUniversity of Copenhagen · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide for 10 months combined, in the initial 8 weeks following diagnosis, with a Very Low Calorie-Diet (max 800 kcal/day)
Timeline
- Start
- 2022-09-02
- Primary completion
- 2025-01-28
- Completion
- 2025-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 2.4 mg | Subcutaneous |